Every material Form 8-K Core Scientific, Inc./tx has filed with the SEC since August 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Core Scientific reported third-quarter 2026 results, with total revenue of $232.9 million, up from $164.2 million in the second quarter and $81.1 million a year earlier. Net income was $1.18 billion, mainly from a non-cash gain tied to changes in the fair value of warrants, compared with a net loss of $1.16 billion in the prior quarter. The company says colocation revenue is growing as it delivers capacity under its first colocation agreement, while construction under its second is underway across five campuses.
Total revenue of $232.9 million for the quarter ended September 30, 2026, versus $164.2 million in Q2 2026 and $81.1 million in Q3 2025.
Net income of $1.18 billion ($0.47 diluted per share), driven mainly by a $1.03 billion gain from the change in fair value of warrants and contingent value rights.
Adjusted EBITDA of $133.6 million, up from $41.1 million in Q2 2026; operating income of $72.4 million versus an operating loss of $78.5 million in Q2 2026.
Colocation revenue of $215.4 million with 485 MW billing as of September 30, 2026; liquidity and DSRA of $1.74 billion, down from $2.60 billion at June 30, 2026.
Core Scientific said ERCOT has conditionally approved power allocations at its Denton, Pecos and Hunt, Texas data centers under different ERCOT pathways. Denton's existing 297 megawatts is conditionally approved as longstanding load and is not subject to the Batch Zero process, while Pecos must wait for the Batch Zero process to conclude before receiving its final allocation and load ramp. The update clarifies how much power each site can expect, but the filing gives no financial figures or timing for when the power will be fully available.
Denton: existing 297 megawatts conditionally approved as Base Load, Pathway (a); additional 74 megawatts validated in ERCOT's 2025 Regional Transmission Plan
Pecos: existing 300 megawatts and an additional 300 megawatts of Studied Load conditionally approved in Batch Zero; final allocation pending conclusion of Batch Zero
Hunt: planned 431 megawatts conditionally approved under Pathway (e); company reports interconnection studies complete and construction has commenced
Core Scientific entered into a credit agreement on August 25, 2026, providing a $100 million revolving credit facility and a $500 million letter of credit facility, with no amounts outstanding at closing. The company said the facilities are expected to release about $300 million of restricted cash, which management says will improve capital efficiency and financial flexibility. The agreement is secured by substantially all company assets and carries covenants limiting debt, liens, dividends and share repurchases.
Credit agreement dated August 25, 2026, with JPMorgan Chase Bank, N.A. as administrative agent and collateral agent
$100 million revolving facility matures in three years, or four at the company's election; $500 million letter of credit facility
Revolver borrowings priced at Adjusted Term SOFR plus 1.75% or alternate base rate plus 0.75%; no amounts outstanding at closing
Company expects the facilities to release approximately $300 million of restricted cash, per CFO Jim Nygaard
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Core Scientific, Inc./tx filing is on SEC EDGAR ↗. 8-K briefs of other companies →